MA-PERKINELMER
17.3.2021 17:05:11 CET | Business Wire | Press release
PerkinElmer , Inc., a global leader committed to innovating for a healthier world, today announced its industry-leading documentation, workflow and decision making Signals™ informatics platform is being expanded to build on existing capabilities in the biologics drug discovery space. This comes through a collaboration with Insightful Science , a software company serving the global life sciences community.
With the collaboration, pharmaceutical and academic research teams can bring together the power of the PerkinElmer Signals™ platform with leading solutions from Insightful Science’s Bioinformatics division. This includes the popular SnapGene and Geneious Prime software offerings that help molecular biologists design and execute DNA construct design, molecular cloning and other kinds of molecular biology research. The integration will give scientists the ability to access and compare data across experiments and instruments and collaborate more intuitively. They can also replicate assays and experiments instantly, leading to faster time-to-result and more informed decision making on drug and vaccine targets.
“There is a limited availability of IT tools in the biologics space,” said Kevin Willoe, VP and GM of PerkinElmer, Informatics. “Through our collaboration with Insightful Science, we’re able to provide enhanced informatics capabilities to scientists doing vital biologics and vaccine research. This will help significantly reduce cycle times for researchers and aid them in making data-driven decisions faster and more accurately - important capabilities when fighting foes like cancer, cardio, neurological and viral diseases.”
"The integration of best-in-class scientific software with cloud-based data platforms is increasingly essential for modern pharmaceutical and biotech enterprises to streamline research and ensure the integrity of valuable data,” added Brett Ammundsen, CEO Bioinformatics at Insightful Science. “The combination of SnapGene and Geneious Prime software with the PerkinElmer Signals platform powerfully enhances research workflows and enriches collaboration. Ultimately this will better connect scientists to their ideas and data, so they can focus on producing life-changing outcomes.”
For more information about the PerkinElmer Signals™ platform, click here . To learn more about Insightful Science, including the Geneious Prime and SnapGene software offerings, visit www.insightfulscience.com .
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
About Insightful Science
Insightful Science is a life sciences software company that digitally connects researchers to their ideas and data, advancing the discovery process. From developing new personalized and preventive patient treatment solutions to reversing climate change — more than 2 million researchers at leading life science and biopharma enterprises trust Insightful Science products to make the world a healthier, cleaner, and better place to live. Products within the Insightful Science portfolio were built by prominent scientists, and include GraphPad Prism, Geneious Prime and Geneious Biologics, SnapGene, nQuery, Cytapex, and more. Visit www.insightfulscience.com for more information about the company and its products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005650/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Planet Prize 2026: Announcement of Prize Laureates10.6.2026 05:00:00 CEST | Press release
This year marks the 35th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions towards the resolution of global environmental problems. The Board of Directors has selected the following 2026 Blue Planet Prize laureates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603774361/en/ Dr. Linda S. Birnbaum (USA), Professor Edward Barbier (USA) 1. Dr. Linda S. Birnbaum (USA) born December 21, 1946 Former Director of the National Institute of Environmental Health Sciences (NIEHS) Former Director of the National Toxicology Program (NTP) Dr. Linda S. Birnbaum led pioneering research on the toxicity of persistent organic pollutants (POPs), significantly advancing international risk assessment. By demonstrating how exposure to
NIQ (NYSE: NIQ) Unveils Six New AI-Powered Capabilities at C360, Executing on Its Vision for Agentic Commerce9.6.2026 21:00:00 CEST | Press release
New capabilities help organizations operationalize trusted market intelligence across enterprise AI environments and workflows, while preparing for the future of agentic commerce NielsenIQ (NYSE: NIQ) today unveiled six new AI-powered capabilities at C360, the company's flagship client and industry event, marking a major milestone in the execution of NIQ’s AI strategy. Thenew capabilities help brands, retailers, and other organizations operationalize trusted market intelligence across enterprise workflows, AI environments, and the emerging world of agentic commerce. NIQ’s AI value creation strategy is built on two foundational principles: Delivering The Full View™: Combining the industry’s broadest and deepest datasets, advanced AI models, and rich content to help organizations unlock actionable insights and drive AI innovation at scale. Enabling AI-Powered Capabilities: Delivering trusted intelligence and proprietary IP through NIQ’s advanced AI applications, assistants, and agents em
H55 Delivers Certification-Grade Propulsion Battery Modules to Pratt & Whitney Canada, Supporting Demonstration of Hybrid-Electric Aircraft Technology9.6.2026 17:31:00 CEST | Press release
Production-conforming systems manufactured in a regulator-approved facility mark H55’s transition from technology development to commercialization of certification-grade energy storage solutions for hybrid-electric aviation. H55 today announced the delivery of certification-grade propulsion battery modules to Pratt & Whitney Canada in support of the RTX Hybrid-Electric Flight Demonstrator — a milestone that further validates H55’s transition from technology development to industrial-scale execution and represents an important step in the commercialization of the company’s certification-grade energy storage technologies for hybrid-electric aerospace applications. Pratt & Whitney is an RTX business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609825006/en/ H55 Adagio Battery Modules in Pratt & Whitney Canada Hangar ©RTX The delivery represents more than hardware integration. It demonstrates H55’s ability to manufacture p
New Polymorph of Indomethacin Discovered9.6.2026 17:00:00 CEST | Press release
- Joint Research Involving Rigaku Published in Crystal Growth & Design - Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; “Rigaku”), announced that the results of a joint research project conducted with Shionogi & Co., Ltd., JEOL Ltd., and Meiji Pharmaceutical University have been published in Crystal Growth & Design, a world-renowned international journal in the field of crystallography. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609347405/en/ Cover of the June 2026 issue of Crystal Growth & Design, featuring this research. This research uncovered a previously unknown polymorph (κ-form) of indomethacin, a widely used pain relief and anti-inflammatory drug. The research team also conducted structural analysis and characterization of the newly identified crystal form. Although indomethacin has
SLB Collaborates with Qualcomm on Edge AI Solutions for Energy Operations9.6.2026 16:28:00 CEST | Press release
Collaboration combines edge computing and energy workflows to support real-time operational decision-making Global energy technology company SLB (NYSE: SLB) today announced a memorandum of understanding with Qualcomm Technologies, Inc. to enable edge AI solutions for the energy industry, supporting real-time operational decision-making across wells, facilities and production systems. The collaboration combines Qualcomm Technologies’ low-power edge computing and AI processing capabilities, with SLB’s Agora™ edge AI and IoT solutions developed for remote and operationally complex environments. “Together, SLB and Qualcomm Technologies aim to help operators apply AI more effectively across energy infrastructure,” said Rakesh Jaggi, president, Digital, SLB. “Many energy operations rely on real-time decision-making in remote environments where connectivity and responsiveness directly affect performance. AI systems designed around the realities of energy operations can help support more consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom